Live Breaking News & Updates on Al Kildani|Page 8

Stay updated with breaking news from Al kildani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027


Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the Convertible Notes ). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act ). The Company granted an option to the initial purchasers to purchase up to an additional $105 million aggregate principal amount of Convertible Notes.
The Convertible Notes will be senior, unsecured, obligations of the Company, will pay interest semi-annually in arrears at an annual rate of 0.25% and under certain circumstances, will be convertible into cash and, if applicable, shares of the Company s common stock, at the Company s electi ....

San Diego , United States , Al Kildani , Bristol Myers Squibb , Exchange Commission , Company Annual Report On Form , Corporate Communications , Halozyme Therapeutics Inc , Halozyme Therapeutics , Convertible Notes , Securities Act , Existing Convertible Notes , Note Repurchases , Share Repurchases , Private Securities Litigation Reform Act , Annual Report , Investor Relations , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , பரிமாற்றம் தரகு , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , பெருநிறுவன தகவல்தொடர்புகள் , மாற்றத்தக்கது குறிப்புகள் , பத்திரங்கள் நாடகம் , இருக்கும் மாற்றத்தக்கது குறிப்புகள் ,

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027


Share this article
Share this article
SAN DIEGO, Feb. 23, 2021 /PRNewswire/  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2027 (the Convertible Notes ). The Convertible Notes are to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act ). The Company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75 million aggregate principal amount of Convertible Notes. ....

San Diego , United States , Al Kildani , Bristol Myers Squibb , Stock Repurchase Program , Halozyme Therapeutics Inc , Company Annual Report On Form , Exchange Commission , Corporate Communications , Board Of Directors The Company , Halozyme Therapeutics , Convertible Notes , Securities Act , Existing Convertible Notes , Note Repurchases , Share Repurchases , Private Securities Litigation Reform Act , Annual Report , Investor Relations , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , பரிமாற்றம் தரகு , பெருநிறுவன தகவல்தொடர்புகள் , பலகை ஆஃப் இயக்குநர்கள் தி நிறுவனம் ,